(Q38040736)

27 August 2017

title

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins (English)

1 reference

27 August 2017

0 references

0 references

Jeffery T Zobell

1

1 reference

27 August 2017

C Dustin Waters

2

1 reference

27 August 2017

David C Young

3

1 reference

27 August 2017

Chris Stockmann

4

1 reference

27 August 2017

Krow Ampofo

5

1 reference

27 August 2017

Catherine M T Sherwin

6

1 reference

27 August 2017

Michael G Spigarelli

7

1 reference

27 August 2017

publication date

4 September 2012

1 reference

27 August 2017

published in

Pediatric Pulmonology

1 reference

27 August 2017

volume

48

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

107-122

1 reference

Management of pulmonary disease in patients with cystic fibrosis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Pharmacokinetics of cefepime in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment--a retrospective analysis in 38 children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Adverse reactions to piperacillin in adults with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Immune-mediated severe hemolytic crisis with a hemoglobin level of 1.6 g/dl caused by anti-piperacillin antibodies in a patient with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Haemolytic anaemia following treatment with piperacillin in a patient with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Antibiotic hypersensitivity in CF: Drug-induced life-threatening hemolytic anemia in a pediatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Transfusion medicine illustrated. Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Treatment of pulmonary infections in patients with cystic fibrosis: A comparative study of ticarcillin and gentamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Antimicrobial therapy of Pseudomonas pulmonary exacerbations in cystic fibrosis. A prospective evaluation of netilmicin plus azlocillin versus netilmicin plus ticarcillin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Pharmacodynamics of tobramycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22669

21 January 2018

Identifiers

DOI

10.1002/PPUL.22669

1 reference

27 August 2017

1 reference